Literature DB >> 17135221

Coronary artery flow velocity profile measured by transthoracic Doppler echocardiography predicts myocardial viability after acute myocardial infarction.

Antti Saraste1, Juha W Koskenvuo, Markku Saraste, Jussi Pärkkä, Jyri Toikka, Alexandru Naum, Heikki Ukkonen, Juhani Knuuti, Juhani Airaksinen, Jaakko Hartiala.   

Abstract

OBJECTIVE: To study whether flow velocity profile in the left anterior descending coronary artery (LAD) measured by transthoracic Doppler echocardiography (TTDE) predicts myocardial viability after reperfused anterior acute myocardial infarction (AMI). PATIENTS AND METHODS: 15 patients who had their first anterior ST elevation AMI and were successfully reperfused by coronary angioplasty and five controls without coronary artery disease were selected. Blood flow velocity spectrum was measured from the mid-LAD by TTDE 3 days after coronary angioplasty. Myocardial viability in the LAD region was quantified 3 months after AMI by relative uptake of 18F-fluorodeoxyglucose (FDG) imaged with positron emission tomography. Myocardium was graded as viable, partially viable or non-viable (relative FDG uptake >85%, 67-85% and <67%, respectively). Main outcome measures were diastolic deceleration time (DDT) of LAD flow velocity 3 days after AMI and myocardial viability 3 months after AMI.
RESULTS: DDT of LAD flow velocity correlated with myocardial FDG uptake in the LAD region (r = 0.91, p<0.01). DDT was markedly longer in patients with viable myocardium (876+/-76 ms, n = 3) than partially viable (356+/-89 ms, n = 6, p<0.01), or non-viable myocardium (128+/-13 ms, n = 6, p<0.01). In controls, DDT was comparable (909+/-76 ms, n = 5) to patients with viable myocardium. DDT <190 ms was always associated with non-viable myocardium.
CONCLUSIONS: DDT of LAD flow velocity is strongly associated with myocardial viability after reperfused anterior AMI. Non-invasive TTDE of the LAD may be used in the acute phase to predict long-term viability of the jeopardised myocardium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135221      PMCID: PMC1861496          DOI: 10.1136/hrt.2006.094995

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

1.  Coronary recanalization in anterior myocardial infarction: the open perforator hypothesis.

Authors:  Paolo Voci; Enrica Mariano; Francesco Pizzuto; Paolo Emilio Puddu; Francesco Romeo
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

2.  Coronary flow velocity analysis during short term follow up after coronary reperfusion: use of transthoracic Doppler echocardiography to predict regional wall motion recovery in patients with acute myocardial infarction.

Authors:  T Hozumi; Y Kanzaki; Y Ueda; A Yamamuro; T Takagi; T Akasaka; S Homma; K Yoshida; J Yoshikawa
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

3.  Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction.

Authors:  K Iwakura; H Ito; S Takiuchi; Y Taniyama; Y Nakatsuchi; S Negoro; Y Higashino; A Okamura; T Masuyama; M Hori; K Fujii; T Minamino
Journal:  Circulation       Date:  1996-09-15       Impact factor: 29.690

4.  Assessing myocardial perfusion with the transthoracic Doppler technique in patients with reperfused anterior myocardial infarction: comparison with angiographic, enzymatic and electrocardiographic indices.

Authors:  Katsuomi Iwakura; Hiroshi Ito; Shigeo Kawano; Atsushi Okamura; Koji Tanaka; Yuya Nishida; Yoshihiro Maekawa; Kenshi Fujii
Journal:  Eur Heart J       Date:  2004-09       Impact factor: 29.983

5.  Persistence of systolic coronary flow reversal predicts irreversible dysfunction after reperfused anterior myocardial infarction.

Authors:  Y Nohtomi; M Takeuchi; K Nagasawa; K Arimura; K Miyata; K Kuwata; T Yamawaki; S Kondo; A Yamada; S Okamatsu
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

  5 in total
  6 in total

1.  Noninvasive assessment of myocardial damage after acute anterior myocardial infarction: myocardial blush grade in conjunction with analysis of coronary flow pattern.

Authors:  Kosuke Goto; Atsushi Takagi; Kotaro Arai; Junichi Yamaguchi; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 2.  What is coronary blood flow reserve? Insights using myocardial contrast echocardiography.

Authors:  Sanjiv Kaul
Journal:  J Echocardiogr       Date:  2011-09-07

3.  Cardiac Function, Perfusion, Metabolism, and Innervation following Autologous Stem Cell Therapy for Acute ST-Elevation Myocardial Infarction. A FINCELL-INSIGHT Sub-Study with PET and MRI.

Authors:  Maija T Mäki; Juha W Koskenvuo; Heikki Ukkonen; Antti Saraste; Helena Tuunanen; Mikko Pietilä; Sergey V Nesterov; Ville Aalto; K E Juhani Airaksinen; Jussi P Pärkkä; Riikka Lautamäki; Kari Kervinen; Johanna A Miettinen; Timo H Mäkikallio; Matti Niemelä; Marjaana Säily; Pirjo Koistinen; Eeva-Riitta Savolainen; Kari Ylitalo; Heikki V Huikuri; Juhani Knuuti
Journal:  Front Physiol       Date:  2012-01-30       Impact factor: 4.566

4.  Intracoronary Levosimendan during Ischemia Prevents Myocardial Apoptosis.

Authors:  Markus Malmberg; Tommi Vähäsilta; Antti Saraste; Juha W Koskenvuo; Jussi P Pärkkä; Kari Leino; Timo Laitio; Christoffer Stark; Aira Heikkilä; Pekka Saukko; Timo Savunen
Journal:  Front Physiol       Date:  2012-02-14       Impact factor: 4.566

5.  The Regulatory Role of Histone Modification on Gene Expression in the Early Stage of Myocardial Infarction.

Authors:  Jinyu Wang; Bowen Lin; Yanping Zhang; Le Ni; Lingjie Hu; Jian Yang; Liang Xu; Dan Shi; Yi-Han Chen
Journal:  Front Cardiovasc Med       Date:  2020-11-30

6.  MicroRNA-532 protects the heart in acute myocardial infarction, and represses prss23, a positive regulator of endothelial-to-mesenchymal transition.

Authors:  Ahmed S Bayoumi; Jian-Peng Teoh; Tatsuya Aonuma; Zhize Yuan; Xiaofen Ruan; Yaoliang Tang; Huabo Su; Neal L Weintraub; Il-Man Kim
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.